Differential ibrutinib sensitivity in Cd79b‐mutant and wildtype subtypes of a novel Myd88‐driven DLBCL mouse model.

Autor:	Flümann, R., Hansen, J., Klein, S., Goldfarb‐Wittkopf, H., Pfeiffer, P., Wirtz, J., Lütz, A. F., Persigehl, T., Büttner, R., Jachimowicz, R., Knittel, G., Reinhardt, H. C.
Předmět:	DIFFUSE large B-cell lymphomas LABORATORY mice ANIMAL disease models B cell receptors B cell differentiation
Zdroj:	Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p547-548, 2p
Abstrakt:	B Conclusions: b Taken together, we refined existing I Myd88 i p.L252p and I BCL2 i -driven MCD/C5 DLBCL mouse models by co-expressing the I Cd79b i p.Y195H mutation. B Methods: b We generated an allele that allows the conditional expression of I Cd79b i p.Y195H (the murine orthologue of I CD79B i p.Y196H) from the endogenous locus and bred it to our established DLBCL mouse models. I Cd79b i -mutant murine lymphomas exhibited increased BCR activation levels, resulting in an increased sensitivity towards BTK inhibition, when compared to I Cd79b i wt control tumors. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text